Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-012701
Filing Date
2025-05-28
Accepted
2025-05-28 16:20:30
Documents
60
Period of Report
2025-04-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 761039
2 EX-31.1 ex31-1.htm EX-31.1 14433
3 EX-31.2 ex31-2.htm EX-31.2 14497
4 EX-32.1 ex32-1.htm EX-32.1 5437
5 EX-32.2 ex32-2.htm EX-32.2 5514
  Complete submission text file 0001641172-25-012701.txt   4116868

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE anix-20250430.xsd EX-101.SCH 31173
7 XBRL CALCULATION FILE anix-20250430_cal.xml EX-101.CAL 43917
8 XBRL DEFINITION FILE anix-20250430_def.xml EX-101.DEF 152400
9 XBRL LABEL FILE anix-20250430_lab.xml EX-101.LAB 273387
10 XBRL PRESENTATION FILE anix-20250430_pre.xml EX-101.PRE 221955
62 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 616337
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

EIN.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-37492 | Film No.: 25995661
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)